3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Lymphoma, Large B-Cell, Diffuse
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Recurrence
4
Burkitt Lymphoma
3
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Neoplasm, Residual
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Biphenotypic, Acute
1
Interventions
Rituximab
168
Cyclophosphamide
142
Peripheral Blood Stem Cell Transplantation
84
fludarabine phosphate
68
Filgrastim
64
Etoposide
63
Radiotherapy
55
Vincristine
47
Prednisone
45
Mycophenolic Acid
44
Melphalan
40
Whole-Body Irradiation
39
Cyclosporine
39
Busulfan
39
Tacrolimus
36
Doxorubicin
34
Cytarabine
33
Lenalidomide
29
Carmustine
28
Antilymphocyte Serum
28
Methotrexate
27
Methylprednisolone
26
Bortezomib
26
Bendamustine Hydrochloride
26
sargramostim
21
ibritumomab tiuxetan
20
obinutuzumab
19
ibrutinib
18
fludarabine
18
Dexamethasone
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, Follicular
×
tisagenlecleucel
×
Clear all
NCT03568461
2025-10-07
ELARA
Novartis
Phase 2
Completed
98 enrolled
9 charts
1 FDA
NCT03610724
2024-06-20
BIANCA
Novartis
Phase 2
Completed
34 enrolled
19 charts